| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.64▲ | 8.64▲ | 8.64▲ | 8.68▲ | 10.09▼ |
| MA10 | 8.61▲ | 8.66▲ | 8.59▲ | 9.09▼ | 9.59▼ |
| MA20 | 8.63▲ | 8.66▲ | 8.78▼ | 9.87▼ | 8.61▲ |
| MA50 | 8.82▼ | 9.00▼ | 9.43▼ | 9.18▼ | N/A |
| MA100 | 9.11▼ | 9.81▼ | 10.01▼ | 8.55▲ | N/A |
| MA200 | 9.93▼ | 10.04▼ | 9.82▼ | 8.30▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.029▲ | 0.041▲ | 0.052▲ | -0.246▼ | 0.100▲ |
| RSI | 51.320▲ | 47.175▼ | 44.401▼ | 41.895▼ | 49.424▼ |
| STOCH | 45.380 | 66.408 | 68.937 | 12.241▼ | 74.173 |
| WILL %R | -28.333 | -15.179▲ | -24.000▲ | -87.333▼ | -55.603 |
| CCI | 59.186 | 57.298 | 39.018 | -69.284 | -0.423 |
|
Monday, June 02, 2025 09:00 AM
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib ...
|
|
Saturday, May 31, 2025 05:26 PM
Actuate Therapeutics, Inc. (NASDAQ:ACTU) has announced breakthrough results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) in previously untreated metastatic ...
|
|
Saturday, May 31, 2025 01:57 PM
Actuate Therapeutics (NASDAQ:ACTU) on Saturday announced encouraging results from a Phase 2 clinical trial testing its experimental cancer drug, elraglusib, in combination with standard chemotherapy ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 8.80 | 8.80 | 8.715 | 8.715 | 6,556 |
| 12/06/25 | 8.54 | 9.248 | 8.24 | 8.61 | 59,500 |
| 11/06/25 | 8.66 | 8.817 | 8.32 | 8.67 | 19,900 |
| 10/06/25 | 8.80 | 8.865 | 8.72 | 8.72 | 9,718 |
| 09/06/25 | 9.095 | 9.35 | 8.65 | 8.71 | 35,800 |
| 06/06/25 | 9.20 | 9.35 | 8.87 | 8.96 | 36,700 |
| 05/06/25 | 9.13 | 9.33 | 8.37 | 9.09 | 59,600 |
| 04/06/25 | 9.98 | 9.98 | 9.08 | 9.11 | 63,307 |
| 03/06/25 | 10.90 | 10.90 | 9.75 | 9.75 | 88,403 |
| 02/06/25 | 11.70 | 11.70 | 9.3584 | 10.59 | 171,124 |
|
|
||||
|
|
||||
|
|